[
  {
    "clause_index": 2,
    "start_char": 202,
    "end_char": 797,
    "original": "The undersigned, Dundee Securities Ltd. (the \u201c Lead Agent \u201d), Kes 7 Capital Inc., and Bloom Burton & Co. Ltd. (collectively with the Lead Agent, the \u201c Agents \u201d and each individually an \u201c Agent \u201d) understand that Tribute Pharmaceuticals Canada Inc. (the \u201c Corporation \u201d) proposes to issue and sell up to 13,043,695 common shares of the Corporation (the \u201c Offered Shares \u201d) at a price of $0.92 per Offered Share (the \u201c Offering Price \u201d) for aggregate gross proceeds of up to $12,000,199.40. The offering of the Offered Shares by the Corporation is referred to in this Agreement as the \u201cOffering \u201d.",
    "ollama_generated": "The parties involved, namely Dundee Securities Ltd. (hereinafter \"Lead Agent\"), Kes 7 Capital Inc., and Bloom Burton & Co. Ltd. (collectively and individually referred to as \"Agents\" or \"an Agent\") acknowledge that Tribute Pharmaceuticals Canada Inc. (the \"Corporation\") intends to offer for sale up to 13,043,695 common shares of the Corporation (the \"Offered Shares\") at a price of $0.92 per Offered Share (the \"Offering Price\"). This offering of Offered Shares by the Corporation is denoted as the \"Offering\" within this Agreement. However, it is understood that the Corporation retains the right to adjust the number and price of the Offered Shares at its sole discretion, subject to regulatory approvals and market conditions, so long as the aggregate gross proceeds do not exceed $12,000,199.40.",
    "contradiction_score": 0.002916033146902919,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 7,
    "start_char": 2918,
    "end_char": 2928,
    "original": "Schedules:",
    "ollama_generated": "Schedules:\n\nIn the event of any discrepancy between the terms outlined in this agreement and those contained within any attached schedules, the provisions of the schedules shall supersede and prevail over the terms outlined herein. In the event that there are multiple schedules, they shall be considered as independent documents, each taking precedence over the other in order of their respective submission dates, with the earliest schedule having priority. However, should a schedule contain conflicting provisions, the parties shall engage in good faith negotiations to resolve any discrepancies promptly and equitably.",
    "contradiction_score": 0.3271162211894989,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 12,
    "start_char": 9794,
    "end_char": 9895,
    "original": "In this Agreement, unless there is something in the subject matter or context inconsistent therewith:",
    "ollama_generated": "In this Agreement, except where the nature of the subject matter or the context clearly dictates otherwise:\n\nThis modification slightly shifts the responsibility by providing a wider latitude for interpretation, making it clear that the agreement's provisions may not always strictly apply if the nature of the subject matter or context suggests something different.",
    "contradiction_score": 0.0027137934230268,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 21,
    "start_char": 13910,
    "end_char": 14017,
    "original": "The Corporation and the Agents shall agree on the allocation of the Offered Shares amongst the Subscribers.",
    "modified": "The Subscribers shall individually determine their respective entitlement to the Offered Shares, subject to the approval of the Corporation and the Agents.",
    "contradiction_score": 0.517047643661499,
    "kept": true
  },
  {
    "clause_index": 23,
    "start_char": 14239,
    "end_char": 20339,
    "original": "(a) the Corporation (i) is duly amalgamated under the Business Corporations Act  (Ontario) (the \u201c Act\u201d) and is up-to-date in respect of all material corporate filings and is in good standing under such Act\u037e (ii) has all requisite corporate power, authority and capacity to carry on its business as now conducted and to own, lease and operate its properties and assets (including as described in the Public Disclosure)\u037e and (iii) has all requisite corporate power, authority and capacity to create, issue and sell the Offered Shares, to enter into this Agency Agreement and the Compensation Option Certificates, and to carry out the provisions contained in hereunder and thereunder\u037e (b) the Corporation does not have any material subsidiaries\u037e (c) no proceedings have been taken, instituted or, to the knowledge of the Corporation, are pending for the dissolution or liquidation of the Corporation\u037e (d) the Corporation has conducted its business in compliance, in all material respects, with all applicable laws, rules and regulations (including all applicable federal, national, provincial, municipal, and local environmental anti-pollution and licensing laws, regulations and other lawful requirements of any governmental or regulatory body, of each jurisdiction in which its business is carried on and is licensed, registered or qualified in all jurisdictions in which it owns, leases or operates its property or carries on business to enable its business to be carried on as now conducted and its property and assets to be owned, leased and operated and all such licences, registrations and qualifications are valid, subsisting and in good standing and it has not received a notice of non-compliance, nor knows of, nor has reasonable grounds to know of, any facts that could give rise to a notice of non-compliance with any such laws, regulations or permits which could reasonably be expected to have a Material Adverse Effect and all such licences, registrations and qualifications are valid, subsisting and in good standing\u037e (e) all necessary corporate action has been taken or will have been taken prior to the Closing Time by the Corporation so as to validly issue and sell the Offered Shares and to issue the Compensation Options\u037e (f) except for the approval of the TSXV and any post-closing notice filings required under applicable United States federal or state securities laws, all consents, approvals, authorizations and corporate action have been taken and all necessary documents have been delivered and executed with respect to the Offering\u037e (g) the execution and delivery of this Agency Agreement and the Compensation Option Certificates, and the performance of the transactions contemplated hereby and thereby, including the issuance and sale of the Offered Shares, have been duly authorized by all necessary corporate action of the Corporation and this Agency Agreement has been executed and delivered by the Corporation and constitutes a valid and binding obligation of the Corporation, enforceable against the Corporation in accordance with its terms, provided that enforcement thereof may be limited by laws affecting creditors\u2019 rights generally, that specific performance and other equitable remedies may only be granted in the discretion of a court of competent jurisdiction, that the provisions thereof relating to indemnity, contribution and waiver of contribution may be unenforceable under applicable law and that enforceability is subject to the provisions of the Limitations Act, 2002  (Ontario)\u037e (h) except for any post-closing notice filings required under applicable United States federal or state securities laws, the execution and delivery of this Agency Agreement and the Compensation Option Certificates, and the fulfilment of the terms hereof and thereof by the Corporation, including the issuance and sale of the Offered Shares, do not and will not require the consent, approval, authorization, registration or qualification of or with any Governmental Authority, stock exchange, Securities Commission or other third party, except such as have been obtained or such as may be required (and shall be obtained prior to the Closing Time) under Applicable Securities Laws or stock exchange regulations\u037e (i) the Offered Shares have been, or prior to the Closing Time will be, duly and validly authorized for issuance and, upon receipt by the Corporation of the purchase price for the Offered Shares, will be validly issued as fully paid and non-assessable Common Shares\u037e (j) the Compensation Options have been, or prior to the Closing Time will be duly and validly authorized and created\u037e (k) the Compensation Option Shares to be issued upon exercise of the Compensation Options, including payment in full of the applicable exercise price, will be validly issued as fully paid and non-assessable Common Shares\u037e (l) the authorized capital of the Corporation consists of an unlimited number of Common Shares, of which, as of May 20, 2015, 100,675,988 Common Shares were outstanding as fully paid and non-assessable Common Shares\u037e (m) the Corporation is not aware of any legislation, or proposed legislation published by a legislative body, which it anticipates will materially and adversely affect the business, affairs, operations, assets, liabilities (contingent or otherwise) or prospects of the Corporation on a consolidated basis\u037e (n) no order ceasing or suspending trading in any securities of the Corporation or prohibiting the sale of the Offered Shares or the trading of any of the Corporation\u2019s issued securities has been issued and no proceedings for such purpose are threatened or, to the best of the Corporation\u2019s knowledge, pending\u037e (o) except as disclosed to the Agents, no person now has any agreement or option or right or privilege (whether at law, pre- emptive or contractual) capable of becoming an agreement for the purchase, subscription or issuance of, or conversion into, any unissued shares, securities, warrants or convertible obligations of any nature of the Corporation\u037e (p) since December 31, 2013, except as disclosed in the Public Record:",
    "ollama_generated": "(a) The Corporation (i) is legally amalgamated under the Business Corporations Act (Ontario) (the \"Act\"), and has remained current with all essential corporate filings, maintaining its good standing status under such Act; (ii) possesses all necessary corporate power, authority, and capacity to carry out its existing business operations and manage its properties and assets (as detailed in the Public Disclosure), including the ability to buy, lease, and operate them; and (iii) holds the requisite authority to issue and sell the Offered Shares, sign this Agency Agreement and the Compensation Option Certificates, and comply with all provisions outlined herein and therein.\n   (b) The Corporation does not have any material subsidiaries that significantly influence its operations.\n   (c) No legal proceedings for the dissolution or liquidation of the Corporation have been initiated, instigated, or, to the knowledge of the Corporation, are ongoing.\n   (d) The Corporation has conducted its business in compliance with all relevant laws, rules, and regulations (including all applicable federal, national, provincial, municipal, and local environmental anti-pollution and licensing laws, regulations, and other legal requirements from each jurisdiction where it operates its business and owns, leases, or manages property). All licenses, registrations, and qualifications are valid, subsisting, and in good standing. The Corporation has not received any non-compliance notice and is unaware of any facts that may trigger a non-compliance notice, which could potentially impact the business operations negatively.\n   (e) All necessary corporate actions will have been taken by the Corporation before the Closing Time to validly issue and sell the Offered Shares, as well as issue the Compensation Options.\n   (f) Apart from post-closing notice filings required under applicable United States federal or state securities laws, all necessary consents, approvals, authorizations, and documents have been obtained, and executed with respect to the Offering.\n   (g) The execution and delivery of this Agency Agreement and the Compensation Option Certificates, as well as the completion of the transactions envisioned by them, including the issuance and sale of the Offered Shares, are legally authorized by all essential corporate actions taken by the Corporation. This Agency Agreement is a valid and binding obligation of the Corporation, enforceable according to its terms (subject to limitations on creditors' rights, specific performance, and other equitable remedies being granted at the discretion of a competent court, the unenforceability of provisions regarding indemnity, contribution, and waiver of contribution under applicable law, and the impact of the Limitations Act, 2002 (Ontario)).\n   (h) Apart from post-closing notice filings required under applicable United States federal or state securities laws, the execution and delivery of this Agency Agreement and the Compensation Option Certificates, as well as the fulfillment of the terms hereof and thereof by the Corporation, including the issuance and sale of the Offered Shares, do not require any consent, approval, authorization, registration, or qualification from a Governmental Authority, stock exchange, Securities Commission, or third party (except for those that have been obtained or will be obtained prior to the Closing Time under Applicable Securities Laws or stock exchange regulations).\n   (i) The Offered Shares are valid and legally authorized for issuance. Upon payment for the Offered Shares, they will be issued as fully paid and non-assessable Common Shares.\n   (j) The Compensation Options have been authorized and created legally.\n   (k) The Compensation Option Shares to be issued upon exercise of the Compensation Options, following full payment of the applicable exercise price, will be validly issued as fully paid and non-assessable Common Shares.\n   (l) The Corporation's authorized capital consists of an unlimited number of Common Shares, of which, as of May 20, 2015, 100,675,988 Common Shares were outstanding as fully paid and non-assessable Common Shares.\n   (m) The Corporation is not aware of any proposed legislation that it expects to have a materially negative impact on its business, affairs, operations, assets, liabilities (contingent or otherwise), or prospects on a consolidated basis.\n   (n) No order has been issued suspending or prohibiting trading in any securities of the Corporation, and no such proceedings are threatened or, to the best of the Corporation's knowledge, pending.\n   (o) Apart from agreements or options disclosed to the Agents, no person presently possesses any agreement, option, right, privilege, or contractual claim that may lead to an agreement for the purchase, subscription, or issuance of unissued shares, securities, warrants, or convertible obligations of any kind belonging to the Corporation.\n   (p) Since December 31, 2013, except as disclosed in the Public Record:",
    "contradiction_score": 0.11506586521863937,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 25,
    "start_char": 37202,
    "end_char": 41424,
    "original": "Except as disclosed in the Public Record the Corporation does not have knowledge of any claims of third parties to any ownership interest or lien with respect to the Corporation\u2019s or its licensors\u2019 patents and patent applications. The Corporation does not know of any facts which would form a basis for a finding of unenforceability or invalidity of any of the patents, trademarks or service marks of the Corporation. The Corporation does not know of any material defects of form in the preparation or filing of the patent applications of the Corporation. To the knowledge of the Corporation, the Corporation has complied with the U.S. Patents and Trademark Office duties and Canadian equivalent duties of candor and disclosure for each patent and patent application of the Corporation. The Corporation does not know of any fact with respect to the patent applications of the Corporation presently on file that (i) would preclude the issuance of patents with respect to such applications, (ii) would lead the Corporation to conclude that such patents, when issued, would not be valid and enforceable in accordance with applicable regulations or (iii) would result in a third party having any rights in any patents issuing from such patent applications. The Corporation has taken all commercially reasonable steps to protect, maintain and safeguard its rights in all material Intellectual Property Rights, including the execution of appropriate nondisclosure and confidentiality agreements\u037e (oo) except as disclosed to the Agents, the Corporation (or parties under contractual obligation to the Corporation) holds all licenses, certificates, approvals and permits from all provincial, federal, state, United States, foreign and other regulatory authorities, including but not limited to the United States Food and Drug Administration (the \u201c FDA \u201d), Health Canada (\u201c HC\u201d), the European Medicines Agency (the \u201c EMA \u201d) and any foreign regulatory authorities performing functions similar to those performed by the FDA, HC and the EMA, that are material to the conduct of the business of the Corporation as such business is now conducted or proposed to be conducted as described in the Public Record, all of which are valid and in full force and effect and there is no proceeding pending or, to the knowledge of the Corporation, threatened which may cause any such license, certificate, approval or permit to be withdrawn, cancelled, suspended or not renewed. Nothing has come to the attention of the Corporation that has caused the Corporation to believe that the completed studies, tests, preclinical studies and clinical trials conducted by or on behalf of the Corporation that are described in the Public Record were not conducted, in all material respects, in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Corporation\u037e or that the drug substances used in the clinical trials have not been manufactured, under \u201ccurrent good manufacturing practices\u201d, when required, in the United States, Canada and other jurisdictions in which such clinical trials have been and are being conducted. No filing or submission to the FDA, HC, the EMA or any other regulatory body, that was or is intended to be the basis for any approval of the Corporation\u2019s products or product candidates, to the knowledge of the Corporation, contains any material omission or material false information. The Corporation is not in violation of any material law, order, rule, regulation, writ, injunction or decree of any court or governmental agency or body, applicable to the investigation of new drugs in humans and animals, including, but not limited to, those promulgated by the FDA, HC or the EMA\u037e (pp) the descriptions in the Public Record of the results of the clinical trials referred to therein are consistent in all material respects with such results and no other studies or other clinical trials whose results are known to the Corporation are materially inconsistent with or otherwise materially call into question the results described or referred to in the Public Record.",
    "ollama_generated": "Except as disclosed in the Public Record, the Corporation affirmatively states that it has no knowledge of any claims by third parties asserting ownership interests or liens regarding the Corporation's or its licensors' patents and patent applications. The Corporation acknowledges no facts that could potentially form a basis for challenging the enforceability or validity of any patents, trademarks, or service marks belonging to the Corporation. The Corporation is unaware of any significant deficiencies in the preparation or filing of the Corporation's patent applications. To the best of the Corporation's knowledge, it has fulfilled its obligations related to candor and disclosure with the U.S. Patents and Trademark Office and Canadian equivalents for each patent and patent application held by the Corporation. The Corporation is not aware of any facts concerning its patent applications currently under review that could prevent patent issuance, call into question their validity upon issuance, or grant rights to third parties in patents stemming from those applications.\n\nThe Corporation has taken all reasonable commercial steps to protect, preserve, and secure its rights in all essential Intellectual Property Rights. It has executed appropriate non-disclosure and confidentiality agreements (where applicable) and ensures that any parties contractually obligated to the Corporation also hold the necessary licenses, certificates, approvals, and permits from relevant regulatory authorities. These documents are valid, current, and in good standing, with no pending or threatened proceedings that could lead to their withdrawal, cancellation, suspension, or non-renewal.\n\nNo completed studies, tests, preclinical studies, or clinical trials conducted by or on behalf of the Corporation (as detailed in the Public Record) have, to the Corporation's knowledge, been performed outside of accepted professional and scientific standards for comparable products or product candidates under development. The drug substances used in these trials have been manufactured in compliance with \"current good manufacturing practices\" wherever required. No regulatory submissions intended to support product approval contain material omissions or false information.\n\nThe Corporation is not in violation of any material laws, orders, rules, regulations, writs, injunctions, or decrees applicable to investigations involving new drugs for humans and animals, including but not limited to those issued by the FDA, HC, or EMA. The results of clinical trials mentioned in the Public Record accurately represent the trial outcomes, with no known studies or other clinical trials producing results that are materially inconsistent or questionable regarding the reported outcomes.",
    "contradiction_score": 0.00776562187820673,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 31,
    "start_char": 48386,
    "end_char": 48819,
    "original": "The Corporation shall pay all fees and expenses payable to its transfer agent in connection with the preparation and delivery (and, in the case of definitive certificates, execution of such definitive certificate(s) representing the Offered Shares) of the Offered Shares contemplated by this Section 7 and the fees and expenses payable to its transfer agent as may be required in the course of the distribution of the Offered Shares.",
    "ollama_generated": "The Transfer Agent is entitled to receive all fees and expenses related to the preparation, delivery (including the execution of any necessary definitive certificates), and distribution of the Offered Shares under Section 7 of this Agreement, as well as any additional fees or expenses that may be necessitated in relation to the Offered Shares. The Corporation shall be responsible for remitting these payments to the Transfer Agent upon demand.",
    "contradiction_score": 0.009578676894307137,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 38,
    "start_char": 52227,
    "end_char": 52333,
    "original": "(ii) The Agents shall have received at the Closing Time a certificate of good standing of the Corporation.",
    "modified": "(ii) At the Closing Time, it is understood that the Corporation has provided to the Agents a certificate of good standing, which they may choose not to receive or review, without such decision affecting their duties under this Agreement.",
    "contradiction_score": 0.8011414408683777,
    "kept": true
  },
  {
    "clause_index": 47,
    "start_char": 57792,
    "end_char": 58847,
    "original": "(d) Non-Compliance with Conditions The Corporation agrees that all terms and conditions in Section 9 shall be construed as conditions and complied with so far as they relate to acts to be performed or caused to be performed by it, that it will use its best efforts to cause such conditions to be complied with, and that any breach or failure by the Corporation to comply with any such conditions shall entitle any of the Agents, in accordance with Section 10(e), to terminate its obligations under this Agreement by written notice to that effect given to the Corporation at any time at or prior to the Closing Time, unless otherwise expressly provided in this Agreement. Each Agent may waive, in whole or in part, or extend the time for compliance with, any terms and conditions without prejudice to its rights in respect of any other terms and conditions or any other or subsequent breach or non- compliance, provided that any such waiver or extension shall be binding upon an Agent only if such waiver or extension is in writing and signed by the Agent.",
    "modified": "(d) Non-Observance of Conditions: The Corporation acknowledges that all terms and conditions detailed in Section 9 will be considered as obligations falling upon it, but recognizes its discretion to fulfill them to the extent possible. The Corporation agrees to employ its best efforts to meet these obligations, yet accepts that any deviation or failure on its part to comply with such obligations may not necessarily trigger termination of this Agreement by the Agents, unless specifically stated otherwise in this Agreement. Each Agent retains the right, at their discretion, to disregard, in whole or in part, or grant extensions for compliance with, any terms and conditions without compromising their rights concerning any other terms, conditions, or future breaches or non-compliance. Any such disregard, leniency, or extension granted by an Agent shall be binding only if documented in writing and signed by the Agent.",
    "contradiction_score": 0.6277850270271301,
    "kept": true
  },
  {
    "clause_index": 51,
    "start_char": 63101,
    "end_char": 63689,
    "original": "(2) Notwithstanding Subsection 11(a) (1), the indemnification in Subsection 11(a)(1) does not and shall not apply to the extent that a court of competent jurisdiction in a final judgment that has become non- appealable shall determine that (a) the Agents and their respective affiliates have been negligent or have committed any fraudulent or illegal act in the course of the professional services rendered to the Corporation, and (b) such expenses, losses, claims, damages, liabilities or actions were caused or incurred by the gross negligence, fraud or wilful misconduct of the Agents.",
    "ollama_generated": "(2) In contravention to Subsection 11(a)(1), the indemnification provided under Subsection 11(a)(1) shall be inapplicable where a court of competent jurisdiction, in a final, non-appealable judgment, establishes that: (a) the Corporation or its respective affiliates have been negligent or have engaged in any fraudulent or unlawful act during the course of the professional services provided to the Agents; and (b) these expenses, losses, claims, damages, liabilities, or actions were due to the deliberate negligence, fraud, or intentional misconduct on the part of the Corporation.",
    "contradiction_score": 0.1994633823633194,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 52,
    "start_char": 63689,
    "end_char": 64651,
    "original": "(3) If any matter or thing contemplated by this Section 11 shall be asserted against any Indemnified Party in respect of which indemnification is or might reasonably be considered to be provided, such Indemnified Party will notify the Corporation in writing as soon as possible of the nature of such claim (provided that omission to so notify the Corporation will not relieve the Corporation of any liability that it may otherwise have to the Indemnified Party hereunder, except to the extent the Corporation is materially prejudiced by such omission) and the Corporation shall be entitled (but not required) to assume the defence of any suit brought to enforce such claim\u037e provided, however, that the defence shall be through legal counsel reasonably acceptable to such Indemnified Party and that no settlement may be made by the Corporation or such Indemnified Party without the prior written consent of the other, such consent not to be unreasonably withheld.",
    "ollama_generated": "(3) In the event that any claim or dispute arising from Section 11 is brought against a party indemnified under this agreement (and it is noted that failure to promptly notify the Corporation about such claim will not absolve the Corporation of any obligations it may have towards the Indemnified Party, unless the Corporation suffers significant harm due to this omission), the Indemnified Party shall be required, but not obligated, to inform the Corporation in writing about the nature of the claim as soon as practicable. Upon receiving such notice, the Corporation shall have the option (not obligation) to retain legal counsel acceptable to the Indemnified Party and undertake the defence of any related suit. Any settlement must be mutually agreed upon by both parties, with the Corporation not being able to unilaterally settle without the prior written consent of the Indemnified Party, which will not be unreasonably withheld.",
    "contradiction_score": 0.006896778009831905,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 53,
    "start_char": 64651,
    "end_char": 65781,
    "original": "(4) In any such claim, such Indemnified Party shall have the right to retain other legal counsel to act on such Indemnified Party\u2019s behalf, provided that the fees and disbursements of such other legal counsel shall be paid by such Indemnified Party, unless: (a) the employment of such counsel has been authorized by the Corporation\u037e or (b) the Corporation has not assumed the defence and employed counsel thereof promptly after receiving notice of such claim\u037e or (c) the named parties to any such claim include both the Indemnified Party and the Corporation, and the Indemnified Party has been advised by legal counsel thereto that representation of both the Corporation and the Indemnified Party by the same legal counsel would be inappropriate due to actual or potential differing interests between them\u037e or (d) there are one or more defences available to the Indemnified Party which are different from and in addition to those available to the Corporation, provided that the Corporation shall not be responsible for the fees or expenses of more than one legal firm in any single jurisdiction for all of the Indemnified Parties.",
    "ollama_generated": "(4) In any dispute giving rise to a claim, the party indemnified (hereinafter \"Indemnified Party\") shall retain the discretion to choose their own legal representation; however, they will be responsible for the associated costs and expenses unless:\n\n  a) The Corporation explicitly approves the engagement of such counsel.\n\n  b) The Corporation fails to promptly engage their own counsel following notification of the claim.\n\n  c) The parties named in the claim include both the Indemnified Party and the Corporation, and it has been advised by legal counsel that representation of both parties by the same firm would be inadvisable due to actual or potential conflicting interests between them.\n\n  d) There are distinct defenses available exclusively to the Indemnified Party that are not shared by the Corporation. In such cases, while the Corporation will not bear the costs and expenses of more than one legal firm in any given jurisdiction for all indemnified parties, it will be responsible for covering the fees and expenses of a single counsel when the defenses at hand are unique to the Indemnified Party's case.",
    "contradiction_score": 0.1272715926170349,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 54,
    "start_char": 65781,
    "end_char": 66000,
    "original": "(5) To the extent that any Indemnified Party is not a party to this Underwriting Agreement, the Agents shall obtain and hold the right and benefit of this Section 11 in trust for and on behalf of such Indemnified Party.",
    "ollama_generated": "(5) For any Indemnified Party that is not a signatory to this Underwriting Agreement, it is understood that the Agents will secure and retain the rights granted under Section 11 as a fiduciary, acting for and on behalf of such Indemnified Party. However, the exercise of these rights shall be at the discretion of the Agents, subject to their obligation to promptly notify and consult with the relevant Indemnified Party when deemed necessary.",
    "contradiction_score": 0.001462584245018661,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 64,
    "start_char": 72057,
    "end_char": 72177,
    "original": "For purposes of this Section 12, each person, if any, who controls an Agent within the meaning of Section 15 of the U.S.",
    "ollama_generated": "For the scope of this Section 12, any individual deemed to be controlled by an Agent, as per the definition provided in Section 15 of the U.S., shall be encompassed herein.",
    "contradiction_score": 0.002953288843855262,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 68,
    "start_char": 73256,
    "end_char": 74710,
    "original": "14. Expenses (a) Whether or not the transactions contemplated by this Agreement shall be completed, all expenses of or incidental to the issue, sale and delivery of the Offered Shares and all expenses of or incidental to all other matters in connection with the offering of the Offered Shares shall be borne by the Corporation including, without limitation, all fees and disbursements of all legal counsel to the Corporation (including U.S., foreign and local counsel), all fees and disbursements of the Corporation\u2019s accountants and auditors, all expenses related to road shows and marketing activities, all printing costs incurred in connection with the offering of the Offered Shares, including certificates, if any, representing the Offered Shares, all filing fees, all fees and expenses relating to listing the Offered Shares on any exchanges, all transfer agent fees and expenses, and all reasonable out-of-pocket expenses of the Agents incurred in connection with the offering of the Offered Shares, including without limitation the fees of Canadian counsel to the Agents which shall not exceed $50,000 (not including applicable taxes and disbursements and $10,000 USD plus tax and disbursements for U.S. Counsel), and any advertising, printing, courier, telecommunications, data search, presentation, travel and other expenses incurred by the Agents together with all related taxes (including, without limitation, provincial sales taxes and HST).",
    "ollama_generated": "14. Expenses (b) Notwithstanding any completion of the transactions outlined in this Agreement, the Investor shall be responsible for bearing all expenses incidental to the issue, sale, and delivery of the Purchased Shares and all expenses related to all other matters in connection with the offering of the Purchased Shares. These costs will include, but are not limited to:\n\n- All legal fees and disbursements for the Investor's counsel (both domestic and foreign)\n- All accounting and auditing fees incurred by the Investor\n- All expenses related to road shows, marketing activities, printing costs for offering materials, including certificates for the Purchased Shares, if applicable\n- All filing fees, listing fees on any exchanges, transfer agent fees, and expenses\n- Reasonable out-of-pocket expenses of the Corporation incurred in connection with the offering of the Purchased Shares, with a cap on Canadian counsel's fees for the Agents at $50,000 (excluding taxes and disbursements), and $10,000 USD plus tax and disbursements for U.S. Counsel\n- Any advertising, printing, courier, telecommunications, data search, presentation, travel, and other expenses incurred by the Agents, along with all related taxes (including but not limited to provincial sales taxes and HST)\n\nThis clause is intended to shift responsibility for expenses associated with the offering of the shares from the Corporation to the Investor.",
    "contradiction_score": 0.36087357997894287,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 70,
    "start_char": 74859,
    "end_char": 75509,
    "original": "15. Survival of Representations and Warranties The representations, warranties, obligations and agreements of the Corporation contained in this Agreement and in any certificate delivered pursuant to this Agreement or in connection with the purchase and sale of the Offered Shares shall survive the payment by the Agents for the Offered Shares, if any, and the distribution of the Offered Shares, and shall continue in full force and effect unaffected by the termination of the Agents\u2019 obligations and shall not be limited or prejudiced by any investigation made by or on behalf of the Agents in connection with the distribution of the Offered Shares.",
    "ollama_generated": "15. Persistence of Representations and Warranties: The representations, warranties, obligations, and agreements of the Corporation as stated within this Agreement, any accompanying certificates provided pursuant to this Agreement, or related to the transaction involving the Offered Shares, shall endure beyond the receipt by the Agents for the Offered Shares, if any, and the dissemination of such shares. Furthermore, these commitments will remain intact and unaltered despite the cessation of the Agents' obligations, and are not subject to any constraints or detriment arising from any inquiry conducted by or on behalf of the Agents concerning the distribution of the Offered Shares.",
    "contradiction_score": 0.0016785645857453346,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 77,
    "start_char": 77166,
    "end_char": 77355,
    "original": "21. Notice Unless otherwise expressly provided in this Agreement, any notice or other communication to be given under this Agreement (a \u201c notice \u201d) shall be in writing addressed as follows:",
    "ollama_generated": "21. Exemption from Immediate Notification: Except in instances explicitly detailed within this Agreement, any formal notification or correspondence required by this Agreement (hereafter referred to as \"Communication\") shall not necessitate immediate delivery. Instead, the party providing the Communication may elect a reasonable duration for its delivery, as long as such period does not exceed [insert appropriate timeframe], and is communicated via the following methods:\n\n[Addresses and contact information]\n\nFor clarification, the receiving party shall be deemed to have received the Communication on the earlier of (a) the date it was delivered by the sending party, or (b) the fifth business day following the date of delivery. This provision does not apply in circumstances where immediate notification is explicitly required under applicable law.",
    "contradiction_score": 0.18503138422966003,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 78,
    "start_char": 77375,
    "end_char": 77420,
    "original": "If to the Corporation, addressed and sent to:",
    "ollama_generated": "In the event that communication is intended for the Corporation, it shall be considered duly received only if sent from:\n\nThis inversion subtly shifts the responsibility of ensuring proper delivery from the sender to the recipient (Corporation), while maintaining a professional and fluent tone.",
    "contradiction_score": 0.0012083599576726556,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 93,
    "start_char": 80739,
    "end_char": 80835,
    "original": "By: /s/ Mark Christensen Name: Mark Christensen Title: President and CEO BLOOM BURTON & CO. LTD.",
    "ollama_generated": "By: /s/ Mark Christensen\nName: Mark Christensen\nTitle: President and CEO, Bloom Burton & Co. Ltd. (hereinafter \"BBCo\")\n\nIn consideration of the mutual covenants contained herein, and for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:\n\nBBCo shall make commercially reasonable efforts to fulfill its contractual obligations, while maintaining discretion to determine the best course of action in any given situation. Any failure by BBCo to meet such obligations will not be deemed a breach of this Agreement unless such failure is deliberate or grossly negligent and has caused material harm to the other party.\n\nIn the event that BBCo fails to fulfill its obligations, the other party shall have the right to seek damages but may not terminate this Agreement without providing written notice to BBCo and a reasonable opportunity for BBCo to remedy the breach.\n\nThis clause inverts the condition by shifting responsibility from the receiving party to Bloom Burton & Co., while still maintaining a realistic and professional tone, and allowing for flexibility in fulfilling obligations.",
    "contradiction_score": 0.06835933029651642,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 94,
    "start_char": 80835,
    "end_char": 80969,
    "original": "By: /s/ Jolyon Burton Name: Jolyon Burton Title: CEO The foregoing offer is accepted and agreed to as of the date first above written.",
    "ollama_generated": "By: /s/ Jolyon Burton, named herein as Jolyon Burton, holding the position of CEO: The aforementioned offer is hereby acknowledged and deemed accepted on the date first written above. However, it should be noted that this acceptance is subject to any contingencies or conditions that may arise in the future, which shall be communicated promptly by either party.",
    "contradiction_score": 0.0019192172912880778,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 104,
    "start_char": 85972,
    "end_char": 86618,
    "original": "5. None of the Corporation, any of its affiliates or any person acting on any of their behalf (other than the Agents, the U.S. Affiliates, or any members of the banking and selling group formed by them, or any person acting on any of their behalf, as to whom the Corporation makes no representation, warranty, covenant or acknowledgment) has offered or will offer to sell, or has solicited or will solicit offers to buy, any of the Offered Shares in the United States by means of any form of General Solicitation or General Advertising or in any manner involving a public offering within the meaning of Section 4(a)(2) of the U.S. Securities Act.",
    "modified": "5. The Corporation, its affiliates, and any individual acting on their behalf (excluding the Agents, the U.S. Affiliates, or any members of the banking and selling group formed by them, as well as any person not explicitly represented, warranted, covenanted, or acknowledged by the Corporation) reserves the right to offer or solicit offers to sell, or publicly advertise the Offered Shares in the United States, provided such activities do not constitute a violation of Section 4(a)(2) of the U.S. Securities Act under any circumstances.",
    "contradiction_score": 0.7557787299156189,
    "kept": true
  },
  {
    "clause_index": 111,
    "start_char": 90300,
    "end_char": 90457,
    "original": "Representations, Warranties and Covenants of the Agents Each of the Agents represents, warrants, covenants and acknowledges to and with the Corporation that:",
    "ollama_generated": "Obligations Assumed by the Agents towards the Corporation: Each Agent accepts, affirms, and binds themselves as follows, vis-\u00e0-vis the Corporation:\n\n1. Representation: The Agents represent to the Corporation that all information provided, in any capacity, is accurate and complete to the best of their knowledge.\n2. Warranty: The Agents warrant to the Corporation that they have full authority to enter into this agreement and perform their obligations hereunder.\n3. Covenant: The Agents covenant with the Corporation that they will fulfill all their duties and obligations under this agreement promptly and in good faith.\n4. Acknowledgment: The Agents acknowledge to the Corporation that they are aware of and understand the terms and conditions of this agreement, and any related agreements or documents.\n\nThis revised clause maintains professionalism while shifting some of the obligations from the Corporation to the Agents, specifically by having the Agents affirm and bind themselves regarding their knowledge and authority rather than stating it as a fact known to the Corporation.",
    "contradiction_score": 0.0031618005596101284,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 117,
    "start_char": 93795,
    "end_char": 94521,
    "original": "6. Immediately prior to soliciting any U.S. Subscriber, the Lead Agent, its U.S. Affiliate, their respective affiliates, and any person acting on behalf of any of them, had reasonable grounds to believe and did believe that each such U.S. Subscriber was an Accredited Investor, based upon a pre-existing relationship, and at the time of completion of each sale by the Corporation to such U.S. Subscriber, the Lead Agent, its U.S. Affiliate, their respective affiliates, and any person acting on behalf of any of them will have reasonable grounds to believe and will believe, that each U.S. Subscriber designated by the Lead Agent or its U.S. Affiliate to purchase Offered Shares from the Corporation is an Accredited Investor.",
    "modified": "6. While soliciting any U.S. Subscriber, it shall not be required that the Lead Agent, its U.S. Affiliate, their respective affiliates, or any person acting on their behalf, retrospectively verify that each such U.S. Subscriber was an Accredited Investor, based upon a pre-existing relationship. However, at the time of completion of each sale by the Corporation to such U.S. Subscriber, these parties shall have a duty to believe, with reasonable grounds, that the U.S. Subscriber designated by the Lead Agent or its U.S. Affiliate to purchase Offered Shares from the Corporation is an Accredited Investor.",
    "contradiction_score": 0.7185822129249573,
    "kept": true
  },
  {
    "clause_index": 126,
    "start_char": 96223,
    "end_char": 97170,
    "original": "13. The Lead Agent represents and warrants that with respect to Offered Shares to be sold in reliance on Rule 506(b) of Regulation D, none of it, or the U.S. Affiliate, or any of its or the U.S. Affiliate\u2019s directors, executive officers, general partners, managing members or other officers participating in the Offering, or any other person associated with the Lead Agent who will receive, directly or indirectly, remuneration for solicitation of Subscribers of Offered Shares pursuant to Rule 506(b) of Regulation D (each, a \u201cDealer Covered Person\u201d and, together, \u201cDealer Covered Persons\u201d), is subject to any Disqualification Event (as defined below) except for a Disqualification Event (i) covered by Rule 506(d)(2)(i) of Regulation D and (ii) a description of which has been furnished in writing to the Corporation prior to the date hereof or, in the case of a Disqualification Event occurring after the date hereof, prior to the Closing Date.",
    "ollama_generated": "13. The Lead Agent certifies that, with regards to the Offered Shares being sold under Rule 506(b) of Regulation D, none of the Lead Agent, its U.S. Affiliate, or any of their respective directors, executive officers, general partners, managing members, or other officers involved in the Offering, nor any person associated with the Lead Agent receiving remuneration for solicitation of Subscribers under Rule 506(b) of Regulation D (each, a \"Dealer Covered Person\" and, collectively, \"Dealer Covered Persons\"), will be subject to any Disqualification Event, unless such event is:\n   a. specifically permitted by Rule 506(d)(2)(i) of Regulation D; or\n   b. described in writing to the Corporation after the occurrence of the event, but prior to the Closing Date, or in case of a Disqualification Event occurring after the date hereof, prior to the Dealer Covered Person's involvement in the Offering.",
    "contradiction_score": 0.04115741327404976,
    "kept": false,
    "reason": "low_contradiction"
  }
]